Design of pyrido[2,3-d]pyrimidin-7-one inhibitors of receptor interacting protein kinase-2 (RIPK2) and nucleotide-binding oligomerization domain (NOD) cell signaling
- 1 April 2021
- journal article
- research article
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 215, 113252
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health
- Wellcome Trust
This publication has 32 references indexed in Scilit:
- A New Class of Small Molecule Inhibitor of BMP SignalingPLOS ONE, 2013
- The Ubiquitin Ligase XIAP Recruits LUBAC for NOD2 Signaling in Inflammation and Innate ImmunityMolecular Cell, 2012
- The Tandem CARDs of NOD2: Intramolecular Interactions and Recognition of RIP2PLOS ONE, 2012
- Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivityNature Biotechnology, 2011
- Signaling via the RIP2 Adaptor Protein in Central Nervous System-Infiltrating Dendritic Cells Promotes Inflammation and AutoimmunityImmunity, 2011
- Inhibition of RIP2's tyrosine kinase activity limits NOD2-driven cytokine responsesGenes & Development, 2010
- Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemiaActa Crystallographica Section D Structural Biology, 2006
- Identification of a regulatory autophosphorylation site in the serine–threonine kinase RIP2Cellular Signalling, 2006
- Nod2 Is a General Sensor of Peptidoglycan through Muramyl Dipeptide (MDP) DetectionJournal of Biological Chemistry, 2003
- Synthesis and Tyrosine Kinase Inhibitory Activity of a Series of 2-Amino-8H-pyrido[2,3-d]pyrimidines: Identification of Potent, Selective Platelet-Derived Growth Factor Receptor Tyrosine Kinase InhibitorsJournal of Medicinal Chemistry, 1998